Aristea has initiated a Phase 2 clinical study to investigate the efficacy and safety of its lead program, RIST4721, in patients with palmoplantar pustulosis (PPP), a rare, chronic inflammatory skin condition with no approved therapy in the United States.

PPP is a debilitating condition that is characterized by repeated outbreaks of treatment-resistant sterile neutrophil filled pustules on the palms of the hands and/or soles of the feet. The pustules and the subsequent cracking of the skin are associated with extreme amounts of pain, itching and burning sensations. Patients with PPP continue to experience physical discomfort and functional disability even after the pustules resolve, making every day activities such as walking, sleeping or working very difficult.

At Aristea, we are committed to helping patients suffering with PPP.